Program

DAY 1 - FRIDAY, MAY 3, 2019
15:00-20:00 Registration
Hotel Lobby, Level 1
18:30-18:45

Welcome
Ballroom 1 and 2, Level 6

18:45-19:30

Keynote Lectures
Ballroom 1 and 2, Level 6

Session Cochairs:
Elizabeth M. Jaffee, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA

Hong Wu, School of Life Science, Peking University, Beijing, China

18:45-19:30

Genome alterations and precision medicine of esophageal squamous-cell carcinoma
Dongxin Lin, Chinese Academy of Medical Sciences, Beijing, China

19:30-21:00

Opening Reception
Ballroom Foyer, Level 6

DAY 2 - SATURDAY, MAY 4, 2019
8:00-10:00

Plenary Session 1: Genomics
Ballroom 1 and 2, Level 6
Session Cochairs:
Mao Mao, SeekIn, Inc., Shenzhen, China
Zemin Zhang, Peking University, Beijing, China

8:00-8:30 Single cell analysis of infiltrating immune cells in multiple cancer types
Zemin Zhang, Peking University, Beijing, China
8:30-9:00 Genetic basis of immunotherapy efficacy
Timothy A. Chan, Memorial Sloan Kettering Cancer Center, New York, NY, USA
9:00-9:30 A comprehensive human gastric cancer organoid biobank that captures molecular diversity and heterogeneity and enable therapeutic screening
Suet Yi Leung, The University of Hong Kong, Hong Kong
9:30-10:00 Identifying occult maternal malignancies via low-coverage whole genome sequencing in 2 million pregnant women
Mao Mao, SeekIn, Inc., Shenzhen, China
10:00-10:20 Break
10:20-11:20

Panel Discussion: FDA Session
Ballroom 1 and 2, Level 6
Moderator: Xiaodong Wang, National Institute of Biological Sciences, Beijing, China
Panelists:
Ke Liu, U.S. Food and Drug Administration, Silver Spring, MD, USA
Zengjun Xu, Center for Drug Evaluation, National Medical Products Administration, Beijing, China

11:30-12:45

Concurrent Sessions 1-2

 

Session 1: Cancer Epigenetics
Ballroom 1 and 2, Level 6

Session Cochairs:
Nilofer S. Azad, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD, USA

Qunying Lei, Fudan University, Shanghai, China

11:30-11:50 Nuclear lactate dehydrogenase A senses ROS to produce an epigenetic metabolite for tumor growth
Qunying Lei, Fudan University, Shanghai, China
11:50-12:10 Epigenome and cistrome-based understanding of prostate cancer susceptibility
Gonghong Wei, University of Oulu, Oulu, Finland
12:10-12:30 Harnessing the immunologic modulatory potential of epigenetic therapy
Nilofer S. Azad, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD, USA
12:30-12:45 Questions / Panel Discussion
 

Session 2: Lung Cancer
Ballroom 3, Level 6

Session Cochairs:
Bruce Robinson, The University of Western Australia, Perth, Australia
Bo Zhu, Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, China

11:30-11:50 Heterogeneity of tumor immune microenvironment in non-small cell lung carcinoma
Bo Zhu, Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, China
11:50-12:10 Lung cancer plasticity and precision medicine
Hongbin Ji, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China
12:10-12:30 Neo-antigens in pulmonary malignancies – overcoming hurdles to neo-antigen immunotherapies 
Bruce Robinson, The University of Western Australia, Perth, Australia
12:30-12:45 Questions / Panel Discussion
13:00-15:45 Poster Session A / Lunch
Han, Level 6
16:00-17:15 Concurrent Sessions 3-4
 

Session 3: Cancer Metabolism
Ballroom 1 and 2, Level 6

Session Cochairs:
Shengcai Lin, Xiamen University School of Life Sciences, Xiamen, China
Tak W. Mak, Campbell Family Institute for Breast Cancer Research, University of Toronto Health Network, Toronto, ON, Canada

16:00-16:20 Therapeutic implications of altered epigenetics and DNA damage responses in hematologic disorders
Tak W. Mak, Campbell Family Institute for Breast Cancer Research, University of Toronto Health Network, Toronto, ON, Canada
16:20-16:40 Pkm1 mediates metabolic advantages and promotes cell-autonomous tumor cell growth
Nobu-hiro Tanuma, Miyagi Cancer Center Research Institute, Natori, Japan
16:40-17:00 Glucose sensing links to control of AMPK and mTOR
Shengcai Lin, Xiamen University School of Life Sciences, Xiamen, China
17:00-17:15 Questions / Panel Discussion
 

Session 4: Leukemia and Lymphoma
Ballroom 3, Level 6

Session Cochairs: 
Xiaojun Huang, Peking University, Beijing, China

Eduardo M. Sotomayor, George Washington University, Washington, DC, USA

16:00-16:20 Cellular therapy for hematologic malignancy disease in China
Xiaojun Huang, Peking University, Beijing, China
16:20-16:40 The evolving landscape of management of multiple myeloma: Immunotherapy and beyond
James CS Chim, Queen Mary Hospital, University of Hong Kong, Hong Kong
16:40-17:00 Targeted Therapy for B-cell Lymphomas: Understanding mechanism(s) of resistance to move the field forward
Eduardo M. Sotomayor, George Washington University, Washington, DC, USA
17:00-17:15 Questions / Panel Discussion
17:15-17:30

Break

17:30-18:45

Concurrent Sessions 5-6

 

Session 5: New Drug Development
Ballroom 1 and 2, Level 6

Session Cochairs:
Brigette B. Ma, Chinese University of Hong Kong, Hong Kong
Zhen Yang, Peking University, Shenzhen, China

17:30-17:50 Overcoming endocrine resistance in breast cancer by selective estrogen receptor covalent antagonist
Ping Zhu, H3 Biomedicine, Cambridge, MA
17:50-18:10 Novel drug combinations to improve the therapeutic ratio of radiotherapy: leveraging on AI to phenotype profiling
Melvin L.K. Chua, National Cancer Center Singapore, Singapore
18:10-18:30 Phase 1 development of new immune-checkpoint inhibitors for solid tumors – lessons learnt and future perspective
Brigette B. Ma, Chinese University of Hong Kong, Hong Kong
18:30-18:45 Questions / Panel Discussion
 

Session 6: Nasopharyngeal Carcinoma
Ballroom 3, Level 6

Session Cochairs:
Anthony T.C. Chan, Chinese University of Hong Kong, Hong Kong 
Chao-Nan Qian, Sun Yat-sen University Cancer Center, Guangzhou, China

17:30-17:50 From uncovering the mechanisms underlying nasopharyngeal carcinoma metastasis to discovering anti-metastasis agents
Chao-Nan Qian, Sun Yat-Sen University Cancer Center, Guangzhou, China
17:50-18:10 Pathogenesis and molecular targets of nasopharyngeal carcinoma
Mu-Sheng Zeng, Sun Yat-Sen University Cancer Center, Guangzong, China
18:10-18:30 Update on systemic therapy in NPC
Anthony T.C. Chan, Chinese University of Hong Kong, Hong Kong
18:30-18:45 Questions / Panel Discussion
DAY 3 -  SUNDAY, MAY 5, 2019

 

8:00-10:00

 

 

Plenary Session 2: Immunotherapy
Ballroom 1 and 2, Level 6
Session Cochairs:
Chen Dong, Tsinghua University, Beijing, China
E
izabeth M. Jaffee, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA

8:00-8:30 Targeted cellular immunotherapy – lessons learned from acute lymphoblastic leukemia
Shannon L. Maude, Children’s Hospital of Philadelphia, Philadelphia, PA, USA
8:30-9:00 Turning the heat up on pancreatic cancer:  Lessons on overcoming a “cold” immunologic micro-environment
Elizabeth M. Jaffee, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
9:00-9:30 Intrinsic tumor genomic and metabolic factors leading to immunoresistance
Patrick Hwu, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
9:30-10:00 New players in cancer immunotherapy- lessons from immune tolerance
Chen Dong, Tsinghua University, Beijing, China
10:00-10:30

Break

10:30-11:45

Concurrent Sessions 7-8

 

Session 7: Male specific cancers: New insights into advanced prostate cancer
Ballroom 3, Level 6

Session Cochairs:
Cory Abate-Shen, Columbia University Irving Comprehensive Cancer Center, New York, NY, USA
Wei-Qiang Gao, Shanghai Jiao Tong University, Shanghai, China

10:30-10:50 Overcome castration-resistant prostate cancer by targeting cancer stem cells, EMT and immune microenvironment
Wei-Qiang Gao, Shanghai Jiao Tong University, Shanghai, China
10:50-11:10 Lineage plasticity as a mechanism of resistance in advanced prostate cancer
Mark A. Rubin, University of Bern, Bern, Switzerland
11:10-11:30 Investigating prostate cancer metastasis using cross-species systems approaches 
Cory Abate-Shen, Columbia University Irving Comprehensive Cancer Center, New York, NY, USA
11:30-11:45 Questions / Panel Discussion
 

Session 8: Female specific cancers
Ballroom 1 and 2, Level 6

Session Cochairs:
Mien-Chie Hung, China Medical University, Taichung, Taiwan/i>
Hui-Kuan Lin, Wake Forest University School of Medicine, Winston Salem, NC, USA

10:30-10:50 New insight for oncogenic Akt signaling and cancer targeting
Hui-Kuan Lin, Wake Forest University School of Medicine, Winston Salem, NC, USA
10:50-11:10 Signal transducing long non-coding RNAs regulating cancer biology
Erwei Song, Sun Yat-Sen University, Guangzhou, China
11:10-11:30 Marker-guided target therapy, PARP inhibitors, and development of effective immune checkpoint therapy
Mien-Chie Hung, China Medical University, Taichung, Taiwan
11:30-11:45 Questions / Panel Discussion
12:00-13:45

Poster Session B / Lunch
Han, Level 6

12:45-13:45

AACR Chemistry in Cancer Research Working Group (CICR) Town Hall
Ballroom 3, Level 6

Host: Zhao-Kui (ZK) Wan, Lynk Pharmaceuticals, Hangzhou, China

14:00-15:15

Concurrent Sessions 9-10

 

Session 9: New Technologies
Ballroom 1 and 2, Level 6

Session Cochairs:
Janis M. Taube, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Fuchou Tang, Peking University, Beijing, China

14:00-14:20 Single-cell multiple omics sequencing of human colorectal cancer
Fuchou Tang, Peking University, Beijing, China
14:20-14:40

Multiplex immunofluorescence: Astronomy accelerates pathology
Janis M. Taube, Johns Hopkins University School of Medicine, Baltimore, MD, USA 

14:40-14:50 Short talk from proffered paper
14:50-15:00 Short talk from proffered paper
15:00-15:15

Questions / Panel Discussion

 

Session 10: Liver Cancer
Ballroom 3, Level 6

Session Cochairs:
Tim F. Greten, National Cancer Institute, Bethesda, MD, USA
Hongyang Wang, National Center for Liver Cancer, Shanghai, China

14:00-14:20 Involvement of cholesterol in HCC progression
Hongyang Wang, National Center for Liver Cancer, Shanghai, China
14:20-14:40 Translating liver cancer biology: From functional target discovery to academic drug discovery and development
Lars Zender, University Hospital Tübingen, Tübingen, Germany
14:40-15:00 Bile acids, the microbiome, immunity & liver tumors
Tim F. Greten, National Cancer Institute, Bethesda, MD, USA
15:00-15:15 Questions / Panel Discussion
15:15-15:30

Break

15:30-16:45

Concurrent Sessions 11-12

 

Session 11: Cancer Prevention
Ballroom 3, Level 6

Session Cochairs:
Adriana Albini, IRCCS MultiMedica, Milan, Italy
You-lin Qiao, Academy of Chinese Medicine, Beijing, China
Additional session chair to be announced

15:30-15:50 Precise prevention of cervical cancer in China
You-lin Qiao, Academy of Chinese Medicine, Beijing, China
15:50-16:10 Precision prevention of cancer: from basic research to clinical practice
Zigang Dong, University of Minnesota Hormel Institute, Austin, MN, USA
16:10-16:30 Dietary derivatives and repurposed drugs for anti-angiogenesis, Chemoprevention, and cancer interception
Adriana Albini, IRCCS MultiMedica, Milan, Italy
16:30-16:45 Questions / Panel Discussion
 

Session 12: GI Cancers
Ballroom 1 and 2, Level 6

Session Cochairs:
Jin Gu, Peking University, Beijing, China
Aida Habtezion, Stanford University School of Medicine, Palo Alto, CA, USA

15:30-15:50 Current status of colorectal cancer surgery in China
Jin Gu, Peking University, Beijing, China
15:50-16:10 Immune signals in GI inflammation and cancer
Aida Habtezion, Stanford University School of Medicine, Palo Alto, CA, USA
16:10-16:20

Short talk from proffered paper

16:20-16:30 Short talk from proffered paper
16:30-16:45 Questions / Panel Discussion
16:45-17:00

Closing Remarks
Ballroom 1 and 2, Level 6